Literature DB >> 27285489

Large local reactions to insect envenomation.

John Carlson1, David B K Golden.   

Abstract

PURPOSE OF REVIEW: Insect stings often induce large local reactions (LLRs) that result in morbidity. These reactions do have an immunologic basis; however, patients presenting with LLRs should be managed differently than those with systemic allergic reactions, as described in this review. RECENT
FINDINGS: Morbidity results from the inflammation itself along with the iatrogenic consequences of treatment. The prescription of antihistamine medications and the use of antibiotics are generally not indicated for patients with LLRs because of the risks/side-effects of these medications and the low probability of benefit. Some patients are also concerned over the possibility that a future sting will evolve into a life-threatening reaction. Although these reactions do involve IgE, patients are not at sufficient risk to warrant prescription of autoinjectable epinephrine. Venom-specific immunotherapy can be considered when LLRs are frequent and associated with significant impairment.
SUMMARY: Clinicians can reduce morbidity from LLRs by reassuring the patients, avoiding medications that result in side-effects when they are not indicated, and referring to an allergist when there are additional concerns, such as frequent impairment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27285489     DOI: 10.1097/ACI.0000000000000289

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  2 in total

1.  Large local reaction to Hymenoptera stings: Sound studies are needed to change a shared concept.

Authors:  Stefano Pucci; Cristoforo Incorvaia; Antonino Romano
Journal:  Immun Inflamm Dis       Date:  2019-09-07

2.  Large local reactions and systemic reactions to insect stings: Similarities and differences.

Authors:  Patrik Tripolt; Lisa Arzt-Gradwohl; Urban Čerpes; Karin Laipold; Barbara Binder; Gunter Johannes Sturm
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.